319 related articles for article (PubMed ID: 22612290)
1. Pharmacokinetics and drug interactions of eslicarbazepine acetate.
Bialer M; Soares-da-Silva P
Epilepsia; 2012 Jun; 53(6):935-46. PubMed ID: 22612290
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers.
Elger C; Bialer M; Falcão A; Vaz-da-Silva M; Nunes T; Almeida L; Soares-da-Silva P
Epilepsia; 2013 Aug; 54(8):1453-61. PubMed ID: 23758485
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures.
Perucca E; Elger C; Halász P; Falcão A; Almeida L; Soares-da-Silva P
Epilepsy Res; 2011 Sep; 96(1-2):132-9. PubMed ID: 21680153
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy.
Almeida L; Minciu I; Nunes T; Butoianu N; Falcão A; Magureanu SA; Soares-da-Silva P
J Clin Pharmacol; 2008 Aug; 48(8):966-77. PubMed ID: 18508949
[TBL] [Abstract][Full Text] [Related]
5. Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers.
Nunes T; Rocha JF; Falcão A; Almeida L; Soares-da-Silva P
Epilepsia; 2013 Jan; 54(1):108-16. PubMed ID: 22812691
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study.
Elger C; Halász P; Maia J; Almeida L; Soares-da-Silva P;
Epilepsia; 2009 Mar; 50(3):454-63. PubMed ID: 19243424
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects.
Nunes T; Sicard E; Almeida L; Falcão A; Rocha JF; Brunet JS; Lefebvre M; Soares-da-Silva P
Curr Med Res Opin; 2010 Jun; 26(6):1355-62. PubMed ID: 20377319
[TBL] [Abstract][Full Text] [Related]
8. The Impact of Pharmacokinetic Interactions With Eslicarbazepine Acetate Versus Oxcarbazepine and Carbamazepine in Clinical Practice.
Johannessen Landmark C; Svendsen T; Dinarevic J; Kufaas RF; Reimers A; Brodtkorb E; Baftiu A; Burns ML; Johannessen SI
Ther Drug Monit; 2016 Aug; 38(4):499-505. PubMed ID: 27414974
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses.
Falcão A; Fuseau E; Nunes T; Almeida L; Soares-da-Silva P
CNS Drugs; 2012 Jan; 26(1):79-91. PubMed ID: 22171585
[TBL] [Abstract][Full Text] [Related]
10. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine.
Zaccara G; Giovannelli F; Maratea D; Fadda V; Verrotti A
Seizure; 2013 Sep; 22(7):528-36. PubMed ID: 23623245
[TBL] [Abstract][Full Text] [Related]
11. Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies.
Shorvon SD; Trinka E; Steinhoff BJ; Holtkamp M; Villanueva V; Peltola J; Ben-Menachem E
J Neurol; 2017 Mar; 264(3):421-431. PubMed ID: 28101651
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, brain distribution and plasma protein binding of carbamazepine and nine derivatives: new set of data for predictive in silico ADME models.
Fortuna A; Alves G; Soares-da-Silva P; Falcão A
Epilepsy Res; 2013 Nov; 107(1-2):37-50. PubMed ID: 24050973
[TBL] [Abstract][Full Text] [Related]
13. Eslicarbazepine acetate for partial-onset seizures.
Rauchenzauner M; Luef G
Expert Rev Neurother; 2011 Dec; 11(12):1673-81. PubMed ID: 22091592
[TBL] [Abstract][Full Text] [Related]
14. Disposition of eslicarbazepine acetate in the mouse after oral administration.
Alves G; Figueiredo I; Castel-Branco M; Lourenço N; Falcão A; Caramona M; Soares-da-Silva P
Fundam Clin Pharmacol; 2008 Oct; 22(5):529-36. PubMed ID: 18710399
[TBL] [Abstract][Full Text] [Related]
15. Exposure-safety and efficacy response relationships and population pharmacokinetics of eslicarbazepine acetate.
Gidal BE; Jacobson MP; Ben-Menachem E; Carreño M; Blum D; Soares-da-Silva P; Falcão A; Rocha F; Moreira J; Grinnell T; Ludwig E; Fiedler-Kelly J; Passarell J; Sunkaraneni S
Acta Neurol Scand; 2018 Sep; 138(3):203-211. PubMed ID: 29732549
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics and Exposure-Response Analyses of Eslicarbazepine Acetate Efficacy and Safety in Monotherapy of Partial-Onset Seizures.
Sunkaraneni S; Ludwig EA; Passarell JA; Blum D; Grinnell T; Fiedler-Kelly J
J Clin Pharmacol; 2018 Jul; 58(7):927-938. PubMed ID: 29528499
[TBL] [Abstract][Full Text] [Related]
17. Post-authorisation study of eslicarbazepine as treatment for drug-resistant epilepsy: preliminary results.
Massot A; Vivanco R; Principe A; Roquer J; Rocamora R
Neurologia; 2014 Mar; 29(2):94-101. PubMed ID: 23623701
[TBL] [Abstract][Full Text] [Related]
18. Effect of eslicarbazepine acetate in the corneal kindling progression and the amygdala kindling model of temporal lobe epilepsy.
Potschka H; Soerensen J; Pekcec A; Loureiro A; Soares-da-Silva P
Epilepsy Res; 2014 Feb; 108(2):212-22. PubMed ID: 24345645
[TBL] [Abstract][Full Text] [Related]
19. Practical guidance and considerations for transitioning patients from oxcarbazepine or carbamazepine to eslicarbazepine acetate--Expert opinion.
Peltola J; Holtkamp M; Rocamora R; Ryvlin P; Sieradzan K; Villanueva V
Epilepsy Behav; 2015 Sep; 50():46-9. PubMed ID: 26114438
[TBL] [Abstract][Full Text] [Related]
20. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate.
Maia J; Almeida L; Falcão A; Soares E; Mota F; Potgieter MA; Potgieter JH; Soares-da-Silva P
Int J Clin Pharmacol Ther; 2008 Mar; 46(3):119-30. PubMed ID: 18397682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
